We earlier published data on 136 children who received hematopoietic SCT (HSCT) for ALL, and showed that early lymphocyte recovery is a powerful indicator for survival by GVL effect without increase in GVHD. To answer the question whether this is true for AML, we extended our cohort to 207 consecutive children with acute leukemia by adding 71 children with AML who received 75 HSCT's between 1994 and 2005. For the AML cohort, all patients at time of HSCT were in complete morphological remission (CR) except for one patient in CR1, who had 8% blasts in the BM before HSCT. All patients received myeloablative regimens. Stem cell sources were: matched sibling donor in 40 patients, mismatched related donor in eight patients, matched unrelated donor in 25 children and two children received cord progenitor stem cells. ALL results were published with significant P-values. In AML, absolute lymphocyte count o0.3 Â 10 9 /l or 40.3 Â 10 9 /l on days 21 and 30 were not predictive of relapse with a hazard ratio at day 21 ¼ 0.88; P ¼ 0.8, and hazard ratio at day 30 ¼ 0.5; P ¼ 0.2.
Introduction
Allogeneic hematopoietic SCT (HSCT) offers the potential for cure in patients with relapsed or high-risk acute leukemia. 1, 2 Relapse is a major risk post HSCT. A total of 30-60% of children with acute myelogenous leukaemia (AML) 3, 4 and 20-40% of patients with ALL eventually relapse post HSCT. 5, 6 The prognosis of patients who relapse post HSCT remains poor. HSCT is effective through two mechanisms: First, tumor reduction by the conditioning regimen, and second, elimination of minimal residual disease through GVL effect. 7, 8 In our earlier study of 136 children with ALL and HSCT, we proved that early lymphocyte recovery is associated with significant GVL effect without increase in GVHD. 9 Nonetheless, historically AML is regarded to be more responsive to GVL effect compared with ALL and this, in part, may be explained by the better response to donor leucocyte infusion (DLI) in AML compared with ALL. 10, 11 Hence, our objective herein was to extend our patient cohort to include all consecutive AML children who received HSCT in our institution and asking the same question, is early lymphocyte recovery post HSCT predictive of survival?
Patients and methods

Patients and donors
This study was approved by our institutional research ethics board. ALL data were published earlier. 9 Only AML data are presented in this report. A total of 75 transplantations were carried out for 71 children with AML. Four patients were transplanted twice. All patients were in complete morphological remission (CR) except for one patient who had 8% blast in the BM sample just before HSCT. Unmanipulated BM graft was given to 69 patients, four received granulocyte CSF peripherally mobilized unmanipulated stem cells and two children received cord progenitor stem cells, one related and one unrelated.
Patient characteristics for the AML cohort are described in Table 1 . The leukocyte counts, both total and differential for days 21 and 30 post HSCT were collected from medical records and electronic database. Two groups were identified on the basis of the absolute lymphocyte count (ALC) of o0.3 Â 10 9 /l and 40.3 Â 10 9 /l for the analysis of the impact of day þ 21 and of day þ 30 ALC on the risk of relapse and survival. When day 21 or day 30 fell on a weekend or there was no differential count available, the ALC 1-2 days before and 1-2 days after days 21 or 30 were taken into account. Patients with a low white cell count that did not allow differential counts or those with non-engraftment at days 21 or 30 were classified to be in the o0.3 Â 10 9 /l groups.
Conditioning regimens
Pre-transplant conditioning regimens varied depending on the donor type and central nervous system (CNS) status at diagnosis or relapse. For related donor transplants, BU and CY regimen was used. BU was given i.v. q6 h Â 16 doses (adjusted as per pharmacokinetics measurement to obtain concentration-time curve of 900-1500 mm min) followed by CY (50 mg/kg per day i.v. Â 4 days). For unrelated donors or those with CNS-positive leukemia, the same dose of CY or a single dose of VP-16 at 60 mg/kg i.v. plus TBI(1200 cGY) in six fractions over 3 days (CY/fTBI-VP16/fTBI) were given. AML subtypes were classified using the FAB (French-American-British) system. Risk definition and cytogenetic abnormalities were classified according to the United Kingdom Medical research Council (UK-MRC) criteria, favorable if t(8;21), t (15) (16) (17) or inversion 16 were present, unfavorable if À5, À7, del (5q), abn (3q), and complex cytogenetics and standard risk for the remaining.
Supportive care
All patients were nursed in protective isolation in single rooms with high-efficiency particulate air (HEPA) filters. All patients received fluconazole for fungal prophylaxis, ganciclovir for CMV prophylaxis if the donor or recipient sero-status for CMV was positive. Pneumocystis jirovecii prophylaxis for at least 6 months post HSCT and pneumococcal prophylaxis with penicillin continued for at least 1-year post HSCT or until vaccinated with pneumococcal vaccine. Fever during the neutropenic phase was treated with broad-spectrum antibiotics, and amphotericin or caspofungen was added when necessary and modified subsequently according to the results of blood or tissue cultures. Blood products were transfused to maintain hemoglobin concentration 470 mg/l and plt counts of Remission status at . CMV-negative patients were transfused with CMV-negative blood products, and all blood products were irradiated.
GVHD prophylaxis
This consisted of MTX and Cyclosporine A (CYA) except for the two patients who received cord progenitor stem cells; the GVHD prophylaxis was with CYA and methylprednisolone. The CYA was administered i.v. at a dose of 3 mg/kg per day in two divided doses starting from the day before stem cell infusion until patients were able to tolerate oral CYA. The dose of CYA was titrated to maintain plasma levels between 150 and 200 ng/l when unrelated donors were utilized as stem cell source and between 100 and 150 ng/l for related donor transplantations. MTX dosage was 10 mg/m 2 i.v. on days þ 3, þ 6, þ 11 and day þ 18.
Assessment of engraftment, GVHD, relapse and TRM
The day of stem cell infusion was defined as day 0. The cells were infused unmanipulated except as required for donorrecipient ABO blood group incompatibility. The minimum cell dose was 2 Â 10 8 nucleated cells per/kg recipient body weight. The day of engraftment was defined as the first of 3 consecutive days in which the peripheral ANC was 40.5 Â 10 9 /l. Acute GVHD was graded as 0-IV according to the criteria of Glucksberg et al. 12 Chronic GVHD was defined as none, limited or extensive according to the standard criteria. 13 Tissue biopsy sample was obtained to confirm the GVHD diagnosis whenever feasible and clinically indicated. Treatment-related mortality was defined as any death in remission. Patients who died from complications of a second transplantation or donor leukocyte infusion therapy given for recurrent disease were defined to have died from disease relapse. Relapse was described by either morphological evidence of disease in the peripheral blood, marrow, extramedullary sites, or by the recurrence and sustained presence of pre-transplant chromosomal abnormalities based on cytogenetic analysis of BM cells.
Endpoints
The primary endpoints of the study were disease relapse or death (event) post HSCT as a measure for the EFS and to assess the role of ALC in predicting the risk of relapse.
Statistical analysis
The SAS software was used to carry out statistical analyses. Time to event and the 3-year probability of EFS for different endpoints was determined using Kaplan-Meier curves. The log-rank test was used to assess the differences between survival curves for the two different groups of patients. The association between pairs of categorical variables was evaluated using Fisher's exact test. The cumulative incidence of relapse and treatment-related mortality at 3-years was estimated taking into account the competing risks of other events. Cox proportional hazard survival model was used to examine multiple prognostic variables impact on survival.
Results
There were 75 transplantations for 71 patients with AML. In the early period of the study, HSCT was offered to all risk patients who had a matched sibling donor. More recently (2000-to date), the UK-MRC risk criteria were utilized and HSCT was offered for the standard risk group if they had a matched sibling donor and for the poor risk group with any donor, related or unrelated. Good risk patients in CR1 were treated with chemotherapy only. A total of 47 patients were transplanted in CR1. The majority of CR1 patients were found to be in standard (intermediate) risk group and most received matched related donor HSCT (81%) using BU/CY as a conditioning regimen. A total of 25 patients were transplanted in CR2, of these, 22 transplanted in CR2 after chemotherapy only and three suffered relapse after first HSCT and received second allogeneic HSCT. Incidentally, the majority of CR2 patients was from the good risk group at the time of original diagnosis and received unrelated donor transplantation upon relapse. Two patients were transplanted in CR3; one was transplanted in CR1, but has relapsed and re-entered remission after DLI and relapsed again, and then received another HSCT, and another patient was transplanted first time in CR3 after suffering another relapse while on salvage chemotherapy. One patient was not in remission before transplant and had 8% blast in the BM just before HSCT. The minimum cell dose was 2 Â 10 /l at day 21 and day 30 post HSCT. Patient's demographics included gender, age at original diagnosis and HSCT, AML FAB type, remission status, length of remission before HSCT in relapsed disease, conditioning regimens, indications of HSCT in CR1 and stem cell source. There were no statistical differences in patient's characteristics between the two groups at day 21 and day 30 taking into account a P-value of 0.1.
Lymphocyte recovery, myeloid engraftment, GVHD and TRM All evaluable patients achieved donor engraftment based on DNA chimerism test or fluorescence in situ hybridization test for xx/xy if there was a gender mismatch between the donor and the recipient and there was no primary graft failure. Serial chimerism/fluorescence in situ hybridization tests monitoring were continued for all patients for at least 3 years post HSCT. The 3-year estimate for treatmentrelated mortality was 16% as 12 children died from treatment-related mortality. One of them died before day 21 and was not evaluable for engraftment and GVHD. Causes of death included infection and severe sepsis in five patients, pulmonary complications in two patients, acute severe GVHD with multi-organ failure in three patients, severe veno-occlusive disease with multi-organ failure in one and cardiac failure in one patient. Table 2 , survival curves are shown in Figures 1 and 2 .
Relapse and EFS
Cox proportional hazard survival model To examine different prognostic variables on survival outcome for the whole cohort (207 children with ALL and AML) who received allogeneic HSCT in addition to the ALC count at days 21 and 30, a Cox proportional hazard survival model was used. Other prognostic variables examined were: patient age, remission status (CR1 vs advanced disease), conditioning regimens (VP16/TBI vs CY/TBI for ALL, BU/CY vs CY/TBI for AML) and donor source (related vs unrelated). The ALC count at days 21 and 30 continued to be the only variable with a significant impact on outcome in ALL patients, but not in AML (data not shown).
Discussion
In this update study of pediatric leukemia receiving allogeneic HSCT, we found that delayed lymphocyte recovery as evidenced by an ALC of o0.3 Â 10 9 /l at day 21 and day 30 post HSCT is not prognostic for AML, as was published earlier for ALL. It is intriguing to realize that GVL effect as measured by these early donor lymphocyte recovery post HSCT matters for lymphoblastic but not myelogenous leukemia despite the fact that, historically, AML is regarded as more GVL-dependent compared with ALL. This pediatric experience is in contrast to the adult AML studies. In a study of 87 adults with AML, Kumar et al.
14 reported that patients with ALC o150 Â 10 6 /l by day þ 30 had a 3.5-fold higher risk of relapse (P ¼ 0.0088) and a lower overall survival (P ¼ 0.0079) than patients with a higher ALC. In that study, the type of GVHD prophylaxis also influenced lymphocyte recovery, as patients receiving prednisone had Table 2 Outcome of HSCT in pediatric AML based on absolute lymphocyte count at day +21 and day +30 studied 201 adult patients with AML and reported that slow lymphocyte recovery in the fourth week after allogeneic HSCT for AML in first remission, as shown by lymphocyte count of o0.2 Â 10 9 /l on day 29, was associated with an increased risk of disease recurrence independent of GVHD. We hypothesize two possibilities for our results; (A) Our AML patient number was too small to answer the question, and a larger multi-centre study is needed. (B) Even with the modest number of our AML patients and within the limitation of a retrospective study, our results are real and early lymphocyte recovery truly has no impact on outcome in HSCT for pediatric AML. Perhaps, the biology of pediatric AML is different from the adult type. Furthermore, the historical belief of AML being more responsive to GVL effect compared with ALL based on DLI response may be misleading. For example, in an earlier study from our institution, we measured GVL effect in children with ALL receiving HSCT by comparing related vs unrelated donor transplant outcomes. Both groups had similar patients characteristics and they were treated exactly the same, with the same conditioning regimens, GVHD prophylaxis and supportive care. However, only incidence of relapse was significantly lower in the unrelated group because of higher incidence of GVHD, proving that GVL is important in pediatric ALL. 16 Furthermore, the very-high-risk infant ALL who benefited from a KIR (killer-cell immunoglobulin-like receptor) mismatch HSCT also proves that GVL is important in ALL. 17 Our understanding of GVL is still limited and there is no good measure for GVL, and although, historically, GVL has been more associated with chronic myeloid leukemia and AML, and may be least effective in ALL based on DLI response, this may be explained by the different disease kinetics of myeloid compared with lymphoid leukemia. The explanation for a more favorable DLI response in the myeloid compared with the lymphoid leukemia could be because it is possible to cure myeloid malignancies with one hit, such as HSCT or DLI, even in frank relapse, whereas it is almost impossible to cure ALL in one hit, ALL cure usually needs maintenance therapy and the likelihood of HSCT or DLI to succeed in ALL is to carry out the procedure in minimal residual or no disease, and therefore, DLI is almost never successful in ALL in frank relapse, but that does not necessarily mean that there is no GVL in ALL and GVL is more effective in AML.
There is a practical significance to monitor lymphocyte recovery post HSCT, this identifies group of patients who may be suitable candidates for early intervention by different immune attack therapy to enhance GVL. Disease burden is at its lowest in early days or weeks after allograft, thus the chances of eliminating it completely through immune mechanism should be the highest. This is possible for children with ALL who have delayed lymphocyte recovery, but not for those with AML, and we still do not have a reliable early post HSCT indicator for relapse to allow early intervention for children with AML. In a recent personal communication from a primary investigator who collected large retrospective data from the international bone marrow transplantation registry (IBMTR) looking at GVHD and outcome in pediatric ALL and AML as a measure for GVL, surprisingly GVHD reduced relapse in ALL but not in AML. We acknowledge the fact that our study results were negative for the AML population, however, we feel it is very important to share this information for a better understanding of GVL kinetics effect in pediatric leukemias and we may need to consider further GVL augmentation strategies, such as KIR mismatch transplants or targeted T-cell therapies to highrisk ALL, and not preserve these strategies only to AML. Furthermore, we acknowledge that GVL exists in AML. However, ALC alone is probably not the best marker for pediatric AML outcome. Further strategies and further studies looking at the exact subsets of these early lymphocytes are warranted.
